(Health Korea News / Lee Si-woo) ENcell, a company specializing in advanced biopharmaceutical CDMO and new drug development, announced on the 26th that it signed a CMO contract with a global top-tier pharmaceutical company.
The main details of this contract were not disclosed due to a confidentiality agreement between the two companies. ENcell explained, “We have already signed contracts with global top-tier pharmaceutical companies such as Novartis and Janssen to provide CMO services, and with this contract, we have secured new customers.”
ENcell says, “We are the only company in Korea equipped with a GMP facility capable of producing cells and viruses simultaneously, and we provide optimal CDMO solutions to our customers through differentiated production and quality control systems along with one-stop service.” insisted.
Jong-wook Jang, CEO of ENCell, said, “This contract with a global top-tier pharmaceutical company served as an opportunity to re-prove the excellence of ENCell’s advanced CDMO service and quality management system.” He added, “To keep up with the continuously increasing demand for CDMO, “We will provide the best service to our customers through more optimized processes and quality control.”
Meanwhile, ENcell began administering the high-dose phase 1b clinical trial of EN001 to patients with Charcot-Marie-Tooth disease type 1A in December. ENcell has confirmed the safety and exploratory treatment effect when administering the low-dose group of EN001, and expects to confirm the same level of effect in the high-dose group, which is twice as high. The plan is to speed up the entry into phase 2 clinical trials by drawing results after completing patient administration within the year.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
